Ex Parte NEERVEN - Page 5

             Appeal 2007-1070                                                                  
             Application 09/467,901                                                            

                   to contact with the IgE receptor to simulate in vivo interactions           
                   between the IgE antibody, the ligand, and the IgE receptor,                 
                         (c) separating the carrier-bound IgE-containing                       
                   complexes from the mixture II, and                                          
                         (d) detecting and/or quantifying physiologically active               
                   forms of ligand-specific IgE bound to said receptor by                      
                   determining the amount of the carrier-bound IgE-containing                  
                   complexes formed by detecting a label present in the carrier-               
                   bound IgE-containing complexes,                                             
                   wherein the label to be detected is associated with the ligand or           
                   the IgE antibody and wherein the label to be detected is added              
                   to the complexes present in steps (a), (b), or (c) and does not             
                   form part of the carrier and wherein in vivo interactions                   
                   between the IgE antibody, the IgE antibody’s ligand and the                 
                   IgE antibody’s receptor are simulated to measure                            
                   physiologically active forms of IgE.                                        

                                      FINDINGS OF ACT                                          
                                           Johansen                                            
             1.  Johansen describes an IgE assay which is specific for an IgE antibody;        
             the IgE antibody recognizes a specific antigen or hapten of interest              
             (Johansen, col. 4, ll. 50-62 and col. 5, ll. 50-60; Answer 4).                    
             2. The assay contains: 1) specific IgE-antibody; 2) a specific allergen           
             (antigen or hapten) bound to biotin; 3) a monoclonal mouse anti-IgE bound         
             to magnetic particles; and 4) a chemiluminescent avidin-acridinium ester          
             label (Johansen, col. 5, ll. 50-60; Answer 4).                                    
             3.  The specific IgE-antibody (present in a “sample”) is mixed with the           
             specific allergen bound to biotin (“ligand antigen”) and the anti-IgE bound       



                                              5                                                

Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  Next

Last modified: September 9, 2013